Develops Plinabulin and other potential cancer medicines for patients, and works with pharmaceutical companies on drug discovery through its SEED subsidiary.
10-K for FY2025, filed Mar 25, 2026We are a clinical stage global biopharmaceutical company focused on developing innovative therapies to improve clinical outcomes for…View ↗
Pharmaceutical companies collaborate with BeyondSpring on drug discovery and product development. Hospitals and investigators conduct Plinabulin studies with the company's financial support and drug supply.
10-K for FY2025, filed Mar 25, 2026
8-K, filed Oct 6, 2026
On September 30, 2026, BeyondSpring Inc. (the “Company”) completed the closing (the “Closing”) of the previously disclosed transactions…View ↗
8-K, filed Jun 4, 2026
Dr. Lan Huang, the current Chief Executive Officer and Chair of the Board of Directors (the “Board”) of the Company, will transition from…View ↗
SEED adds a partner and clinical candidate
The older report described SEED's protein-degradation work with Eli Lilly; the latest report also names Eisai and says SEED's wholly owned cancer candidate has advanced into clinical studies.
20-F for FY2022, filed Apr 18, 2023 10-K for FY2025, filed Mar 25, 2026We are a clinical stage global biopharmaceutical company focused on using its novel technology platform for drug discovery and development…View ↗
We are a clinical stage global biopharmaceutical company focused on developing innovative therapies to improve clinical outcomes for…View ↗
Competes with Bristol-Myers Squibb, Merck &, and Eli Lilly
10-K for FY2025, filed Mar 25, 2026There are a number of large pharmaceutical and biotechnology companies that currently market and sell drugs or are pursuing the development…View ↗
Loading...